Travere Therapeutics, Inc.
TVTX· Nasdaq
TVTXTravere Therapeutics, Inc.
Filed Feb 24, 2022 · 10-K · 55 days after period end · 0001438533-22-000008
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | — | $50.98M | $46.69M | $43.77M |
| Net Income | -$51.57M | -$121.62M | -$30.26M | -$7.46M |
| EPS Diluted | — | -$2.37 | -$0.70 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end
